Multicentre Clinical Study of Ultra-Fast-Track Anaesthesia for Minimally Invasive Heart Valve Surgery
Launched by ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL · Aug 2, 2024
Trial Information
Current as of July 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new approach called ultra-fast-track anesthesia (UFTA) for patients undergoing minimally invasive heart valve surgery. The main goal is to see if this type of anesthesia can help patients recover more quickly after surgery, reduce complications, and improve overall survival rates. Researchers also want to find out if it makes patients feel more satisfied with their care and helps lower healthcare costs.
To be eligible for this study, participants need to be adults aged 18 to 80 who are in good health, with a few specific heart function criteria. Patients will receive standardized care during their hospital stay, and they will be asked to fill out quality of life questionnaires at various points after their surgery to track their recovery. This trial aims to provide valuable insights that could improve recovery experiences for future patients while also considering the financial aspects of care.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥18 and ≤80 years
- • American Society of Anaesthesiologists (ASA) class I-III
- • New York Heart Association (NYHA) cardiac class III or below
- • Preoperative inspired air pulse oximetry (SpO2) ≥95%
- • Ejection fraction (EF) ≥ 40%
- • No contraindications to nerve blocks
- Exclusion Criteria:
- • Patient's refusal to participate
- • Severe communication disorders
- • Severe disorders of coagulation with spontaneous bleeding tendency
- • Long-term application of opioid analgesics
- • Pulmonary hypertension (mean pulmonary artery pressure ≥55 mmHg)
- • People who need artificial ventilation
- • Allergy to dexmedetomidine and ropivacaine
- • Complex aortic root surgery such as root widening
About Zhejiang Provincial People's Hospital
Zhejiang Provincial People's Hospital is a leading medical institution located in Hangzhou, China, renowned for its commitment to advancing healthcare through research and clinical excellence. As a prominent clinical trial sponsor, the hospital integrates cutting-edge medical research with state-of-the-art patient care, facilitating innovative studies across various therapeutic areas. With a team of experienced medical professionals and researchers, Zhejiang Provincial People's Hospital aims to contribute significantly to the development of new treatments and therapies, ensuring the highest standards of ethical practices and patient safety in all its clinical trials.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Mei J Yan, QC
Study Chair
Zhejiang Provincial People's Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported